Clinical Trial Update: Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating oral epalrestat in pediatric subjects with PMM2-CDG has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phosphomannomutase Deficiency

Drugs mentioned

• epalrestat (epalrestat)

Snippet

Sponsor: Maggie's Pearl, LLC | Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 3 | Status: TERMINATED